Cancer Res:哪些肺癌患者会转移 血液活检早期就可告诉您

2017-09-01 贾朝娟 环球医学

密歇根大学的一个研究小组的研究显示,通过血液检测获得的癌细胞或可预测早期肺癌患者的预后。这些信息可以用来确定哪些患者最有可能受益于额外的治疗,以阻止癌症扩散到身体的其他部位。

密歇根大学的一个研究小组的研究显示,通过血液检测获得的癌细胞或可预测早期肺癌患者的预后。这些信息可以用来确定哪些患者最有可能受益于额外的治疗,以阻止癌症扩散到身体的其他部位。

密歇根大学综合癌症中心提供一种新的单细胞分析服务,研究人员正在使必要的技术更广泛地应用于大学系统。他们希望在未来五年内为病人提供这些“液体活检”。

循环肿瘤细胞,仅占血液细胞中的十亿分之一,在很大程度上是未被开发的肿瘤信息来源,但新方法可带来更接近患者治疗的诊断价值。

密歇根大学化学工程设计教授Sunitha Nagrath设计可以捕获这些稀有细胞的设备,领导了一个包括肿瘤专家和外科医生在内的团队,探索癌细胞如何逃离肿瘤和通过血液在身体里穿行。这也就是身体内肿瘤转移或卫星肿瘤如何形成。

Nagrath表示,甚至在肿瘤很小的时候,肿瘤细胞已经开始不断脱落,这是我们学到的一件事。虽然我们将肿瘤定义为早期,但它们已经在体内传播细胞。

早期肺癌患者,肿瘤直径可能只有几毫米,通常采用手术切除肿瘤,但研究结果表明这可能远远不够。少数肿瘤病人会有成百上千的肿瘤细胞进入肺部。

Nagrath表示,即使你切除了肿瘤,但留下了这些成千上百的细胞。如果你知道这些患者走出诊所,因为这些细胞在不到一年的时间里复发,为什么我们现在不治疗他们呢?

在一个相对较小样本的36例患者中,团队不能明确地指出一个积极脱落的肿瘤在一年之内将导致转移,但Nagrath探索了从血液中提取的肿瘤细胞的预测能力。尤其是,研究显示两个或两个以上的肿瘤细胞群表明生存时间更短。在2~26个月的随访期间,9例癌症复发患者中的6例出现成簇的循环肿瘤细胞。

协调血液样本和设计了这一研究的密西根大学外科学教授Rishindra Reddy与密歇根大学医学院医学肿瘤学副教授Nithya Ramnath表示,最终这将帮助我们寻找肿瘤转移和发现肿瘤的潜在标记物。

侵袭性细胞群

遗传分析证实,成簇的细胞表现出较高的攻击性特征。他们更擅长移动、逃避免疫系统、招募血细胞帮助他们和抵抗治疗。换句话说,成簇的肿瘤细胞更适合将癌症传播到遥远的地方。

Nagrath表示,这些是肿瘤进展和抵抗的驱动力,对于针对性的治疗它们更为重要。

为了收集支持这一发现的数据,研究小组在切除肿瘤术前、中、后采集血样。在每个阶段,外科医生从病人远离肿瘤的手臂静脉中收集血液。在外科手术早期,干扰肿瘤之前,外科医生还从肺静脉抽取从肿瘤中排出的血液,预计此处的肿瘤细胞会更加集中。

然后,Nagrath实验室博士生Vasudha Murlidhar使用自己设计的微流控芯片分析了所有的样品。尽管来自手臂的肿瘤细胞平均计数为每3毫升1.3个,来自肺的血液则为每3毫升7.5个。在肺血样本中出现成百上千肿瘤细胞的患者中,当细胞进入手臂静脉时细胞数量急剧下降。

它不能仅仅通过稀释来解释。研究人员推测,较大的团簇会陷在毛细血管中——可能是新肿瘤的开始——或者说,其中许多细胞在血流中无法存活。

用血液检测监测癌症

Nagrath迫不及待地想要看到液体活检已经开始让密歇根的患者受益。这项研究表明,从血液中捕获癌细胞能表明哪些患者需要第二次治疗,如化疗,去消灭已经分散在体内的细胞。它还可以帮助医生更好地选择可更好攻击这些侵袭性细胞弱点的药物。

Nagrath正在与密歇根大学推进这一技术。新的单细胞分析核心将使用许多不同的微流控芯片从血液中分离癌细胞。

医学院泌尿学教授Evan Keller将领导细胞分析技术。这一努力将主要帮助癌症研究人员更好地理解疾病,但Nagrath希望液体活检成为密歇根医学常规治疗的一部分将不会是很久远的事情。

Nagrath表示,通过简单的抽血,我们可以在治疗期间和治疗后判断病情的动态,密切监测病情。如果有CT扫描显示有东西存在,它可能已经太晚了。

原始出处:

Vasudha Murlidhar, Rishindra M Reddy, Shamileh Fouladdel, et.al. Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early Stage Lung Cancers. Cancer Research

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990606, encodeId=045d199060649, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Nov 10 03:53:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059047, encodeId=2455205904e61, content=<a href='/topic/show?id=ecc4892996d' target=_blank style='color:#2F92EE;'>#血液活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89299, encryptionId=ecc4892996d, topicName=血液活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sun Jun 03 13:53:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278034, encodeId=f07712e8034f4, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 03 00:53:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239508, encodeId=3168239508a4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sat Sep 02 00:18:37 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239364, encodeId=c2af239364fb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Sep 01 15:32:22 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239316, encodeId=12d8239316b7, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Sep 01 13:14:47 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239277, encodeId=828b2392e781, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Fri Sep 01 10:26:39 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239271, encodeId=44832392e180, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Sep 01 09:59:25 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990606, encodeId=045d199060649, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Nov 10 03:53:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059047, encodeId=2455205904e61, content=<a href='/topic/show?id=ecc4892996d' target=_blank style='color:#2F92EE;'>#血液活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89299, encryptionId=ecc4892996d, topicName=血液活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sun Jun 03 13:53:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278034, encodeId=f07712e8034f4, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 03 00:53:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239508, encodeId=3168239508a4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sat Sep 02 00:18:37 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239364, encodeId=c2af239364fb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Sep 01 15:32:22 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239316, encodeId=12d8239316b7, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Sep 01 13:14:47 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239277, encodeId=828b2392e781, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Fri Sep 01 10:26:39 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239271, encodeId=44832392e180, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Sep 01 09:59:25 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990606, encodeId=045d199060649, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Nov 10 03:53:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059047, encodeId=2455205904e61, content=<a href='/topic/show?id=ecc4892996d' target=_blank style='color:#2F92EE;'>#血液活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89299, encryptionId=ecc4892996d, topicName=血液活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sun Jun 03 13:53:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278034, encodeId=f07712e8034f4, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 03 00:53:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239508, encodeId=3168239508a4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sat Sep 02 00:18:37 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239364, encodeId=c2af239364fb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Sep 01 15:32:22 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239316, encodeId=12d8239316b7, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Sep 01 13:14:47 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239277, encodeId=828b2392e781, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Fri Sep 01 10:26:39 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239271, encodeId=44832392e180, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Sep 01 09:59:25 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-03 smlt2008
  4. [GetPortalCommentsPageByObjectIdResponse(id=1990606, encodeId=045d199060649, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Nov 10 03:53:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059047, encodeId=2455205904e61, content=<a href='/topic/show?id=ecc4892996d' target=_blank style='color:#2F92EE;'>#血液活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89299, encryptionId=ecc4892996d, topicName=血液活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sun Jun 03 13:53:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278034, encodeId=f07712e8034f4, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 03 00:53:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239508, encodeId=3168239508a4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sat Sep 02 00:18:37 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239364, encodeId=c2af239364fb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Sep 01 15:32:22 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239316, encodeId=12d8239316b7, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Sep 01 13:14:47 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239277, encodeId=828b2392e781, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Fri Sep 01 10:26:39 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239271, encodeId=44832392e180, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Sep 01 09:59:25 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-02 luominglian113

    学习了.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1990606, encodeId=045d199060649, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Nov 10 03:53:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059047, encodeId=2455205904e61, content=<a href='/topic/show?id=ecc4892996d' target=_blank style='color:#2F92EE;'>#血液活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89299, encryptionId=ecc4892996d, topicName=血液活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sun Jun 03 13:53:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278034, encodeId=f07712e8034f4, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 03 00:53:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239508, encodeId=3168239508a4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sat Sep 02 00:18:37 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239364, encodeId=c2af239364fb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Sep 01 15:32:22 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239316, encodeId=12d8239316b7, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Sep 01 13:14:47 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239277, encodeId=828b2392e781, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Fri Sep 01 10:26:39 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239271, encodeId=44832392e180, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Sep 01 09:59:25 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 明天会更好!

    学习了.谢谢分享.

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1990606, encodeId=045d199060649, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Nov 10 03:53:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059047, encodeId=2455205904e61, content=<a href='/topic/show?id=ecc4892996d' target=_blank style='color:#2F92EE;'>#血液活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89299, encryptionId=ecc4892996d, topicName=血液活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sun Jun 03 13:53:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278034, encodeId=f07712e8034f4, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 03 00:53:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239508, encodeId=3168239508a4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sat Sep 02 00:18:37 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239364, encodeId=c2af239364fb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Sep 01 15:32:22 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239316, encodeId=12d8239316b7, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Sep 01 13:14:47 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239277, encodeId=828b2392e781, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Fri Sep 01 10:26:39 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239271, encodeId=44832392e180, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Sep 01 09:59:25 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1990606, encodeId=045d199060649, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Nov 10 03:53:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059047, encodeId=2455205904e61, content=<a href='/topic/show?id=ecc4892996d' target=_blank style='color:#2F92EE;'>#血液活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89299, encryptionId=ecc4892996d, topicName=血液活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sun Jun 03 13:53:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278034, encodeId=f07712e8034f4, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 03 00:53:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239508, encodeId=3168239508a4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sat Sep 02 00:18:37 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239364, encodeId=c2af239364fb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Sep 01 15:32:22 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239316, encodeId=12d8239316b7, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Sep 01 13:14:47 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239277, encodeId=828b2392e781, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Fri Sep 01 10:26:39 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239271, encodeId=44832392e180, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Sep 01 09:59:25 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 执着追梦

    学习.谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1990606, encodeId=045d199060649, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Nov 10 03:53:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059047, encodeId=2455205904e61, content=<a href='/topic/show?id=ecc4892996d' target=_blank style='color:#2F92EE;'>#血液活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89299, encryptionId=ecc4892996d, topicName=血液活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sun Jun 03 13:53:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278034, encodeId=f07712e8034f4, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 03 00:53:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239508, encodeId=3168239508a4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sat Sep 02 00:18:37 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239364, encodeId=c2af239364fb, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Sep 01 15:32:22 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239316, encodeId=12d8239316b7, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Sep 01 13:14:47 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239277, encodeId=828b2392e781, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Fri Sep 01 10:26:39 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239271, encodeId=44832392e180, content=非常好的文章.学习了.很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Sep 01 09:59:25 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 天涯183

    非常好的文章.学习了.很受益

    0

相关资讯

JCO:研究确定了B族维生素补充与肺癌的关系!

新的研究表明,长期高剂量补充维生素B6和B12(长期以来被维生素工业所吹捧,以增加能量和改善新陈代谢 )- 对男性而言,肺癌风险增加了两到四倍。

Ann Oncol:免疫检查点抑制剂对NSCLC的二线治疗的成本效益和经济影响如何?

背景:免疫检查点抑制剂能改善肺癌化疗的疗效。肿瘤细胞PD-L1受体的表达一直被作为一种生物标志物被研究。本研究的目的是在选择性治疗患者中评估肿瘤二线疗法中的纳武单抗、派姆单抗和Atezolizumab与/不与PD-L1联用的成本效益和经济影响。设计:研究人员开发了一个决策分析模型,以确定PD-L1和二线免疫治疗vs多西他赛的成本效益。该模型使用了来自美国的随机临床试验(RCT)和药品采购成本的结果

美国国家癌症数据库:胸腔镜肺叶切除术是否能改善早期肺癌的长期预后?

根据美国国家癌症数据库的研究结果,I期非小细胞肺癌(NSCLC)患者接受电视辅助胸腔镜手术(VATS)肺叶切除术治疗,住院时间更短,且患者的长期生存率不低于开放肺叶切除术治疗者。

维生素B和肺癌之间有明显的联系

一项新的研究表明,与非使用者相比,长期、高剂量的补充维生素B6和B12的男性患肺癌的风险增加了两到四倍。维生素B6和B12长期以来被维生素工业吹捧具有补充能量和改善新陈代谢的作用。男性吸烟者在10年内每天服用20毫克维生素B6或55毫克维生素B12的风险进一步升高。与非吸烟者相比,服用该剂量维生素B6的男性吸烟者患肺癌的几率高出三倍。服用维生素B12的男性吸烟者罹患肺癌的可能性要高出大约四倍。来自

CLIN CANCER RES:肺癌瘤内注射CCL21基因修饰的DC细胞可以诱导肿瘤特异性免疫反应及CD8+T细胞浸润

CLIN CANCER RES近期发表一篇文章,评估了瘤内局部注射肿瘤疫苗的安全性及肿瘤抗原特异性免疫反应。晚期非小细胞肺癌(NSCLC)患者接受瘤内注射转载了表达CCL21基因腺病毒载体的自体DC细胞(Ad-CCL21-DC)。

上海市肺科医院肿瘤科周彩存团队创造肺癌诊疗“中国速度”,惊艳世界!

近日,上海市肺科医院肿瘤科周彩存教授团队的苏春霞教授在英国马斯登皇家医院访学期间应邀在欧洲癌症协会(ECC)和欧洲癌症研究和治疗组织(EORTC)官方期刊杂志European Journal of Cancer(2016年影响因子6.029),系统地介绍了其团队历时近十年,创造的晚期肺癌精准化诊疗路径。这是我国肺癌诊疗体系第一次获得国际同行的高度评价,也是我国晚期肺癌诊疗水平已经走在世界前列的标志